In stock COA-30%
NOVALYTE
LABS
LABS
NOVALYTELABS
Oral Semaglutide10mg · RESEARCH USE ONLY
Oral Semaglutide10mg · RESEARCH USE ONLY
In stock COA DOCUMENT SLOT-30%
Metabolic ResearchOral Semaglutide
Oral formulation of semaglutide with SNAC absorption enhancer — the compound behind Rybelsus — for oral GLP-1 research.
Research catalogueLaboratory-use positioning
Batch documentationBatch certificate supplied with order
Order trackingFrom payment to dispatch
Product information
CompoundOral Semaglutide
Presentation10mg injection pen
CategoryMetabolic Research
AvailabilityIn stock
Batch COACertificate supplied with order
For research use only. Not for human consumption, diagnostic, therapeutic or veterinary use.
Overview
Oral Semaglutide is the tablet formulation of semaglutide co-formulated with SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate), an absorption enhancer that enables gastrointestinal uptake of the peptide. Marketed as Rybelsus by Novo Nordisk, it was the first oral GLP-1 receptor agonist to receive regulatory approval. Recent clinical data from the OASIS 1 trial with a higher 50mg dose showed up to 17.4% weight loss — approaching the efficacy of injectable semaglutide. The oral formulation removes the injection barrier while maintaining the established semaglutide pharmacological profile.
Mechanism of Action
SNAC creates a localised increase in gastric pH around the tablet, protecting semaglutide from pepsin degradation while promoting transcellular absorption across the gastric epithelium. Once absorbed, oral semaglutide acts identically to injectable semaglutide — binding GLP-1 receptors to stimulate insulin secretion, suppress glucagon, delay gastric emptying, and activate hypothalamic satiety centres. The C-18 fatty di-acid modification enables albumin binding, extending the half-life to support once-daily oral dosing. Bioavailability is approximately 1% — low but sufficient due to high receptor potency.
Research Applications
- Oral peptide delivery and SNAC enhancer technology research
- GLP-1 receptor agonism via oral vs injectable routes comparison
- Gastric absorption and peptide bioavailability studies
- Metabolic research with non-injectable GLP-1 compounds
- Oral peptide pharmacokinetics and dose-response investigation